Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Pertuzumab, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) for reimbursement as a treatment option for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment. The regime further states that patients should have already been treated with pertuzumab and trastuzumab in combination with DOCEtaxel, PACLItaxel, or vinorelbine.
This statement is based on a regulatory approval from the Health Service Executive:
Pertuzumab/ trastuzumab (Phesgo) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.